Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
763.650.02%
QQQ
706.190.02%
BTC/USD
80799.002.2953%
DIA
533.600.01%
GLD
429.100.56%
TLT
82.630.08%

Editas Medicine Inc

EDITNASDAQ
Trade with Public
Trade with Public
$3.00
-0.11-3.54%
At close: Aug 24, 5:00 PM EST
$3.00
0.00080.03%
After Hours: 6:37 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Editas Medicine Analyst Price Targets

Wall Street analyst price targets and consensus rating for Editas Medicine (EDIT).

Price Target Range — 11 Quarters

Analyst Consensus — 13 Analysts

9Buy
3Hold
1Sell
Consensus RatingBuy# Analysts13Avg. Consensus PT$7Upside to Avg. PT+139.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 18, 2026Ladenburg Thalmann—InitiateBuy$6
May 5, 2026Chardan CapitalGeulah LivshitsPT RaiseBuy$4→$4
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $4

Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $3.5 to $4.
Benzinga Newsdesk

PRO
Jones Trading Upgrades Editas Medicine to Buy, Announces $8 Price Target

Jones Trading analyst Soumit Roy upgrades Editas Medicine (NASDAQ:EDIT) from Hold to Buy and announces $8 price target.
Benzinga Newsdesk

Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Benzinga Insights

PRO
HC Wainwright & Co. Reiterates Buy on Editas Medicine, Maintains $5 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Editas Medicine (NASDAQ:EDIT) with a Buy and maintains $5 price target.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Editas Medicine, Raises Price Target to $4

Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and raises the price target from $3 to $4.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Editas Medicine, Raises Price Target to $5

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $3 to $5.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved